Ziltivekimab Lowered Inflammation Marker CRP 64% in Heart and Kidney Patients Without Preventing Heart Attacks or Strokes
The ZEUS trial found that ziltivekimab significantly lowered inflammation markers but did not reduce heart attacks, strokes or cardiovascular deaths among high-risk patients with heart and kidney disease.
Medical Daily ·